Aditxt, Inc.
ADTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ADTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADTX
Aditxt, Inc. is a clinical-stage biotechnology company focused on developing immunomodulatory therapies, including a preclinical candidate for Type 1 Diabetes (T1D), with a limited operating history and significant going concern risks due to insufficient capital to fund operations beyond the near term.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2026.
Aditxt, Inc. is a clinical-stage biotechnology company focused on developing immunomodulatory therapies, including a preclinical candidate for Type 1 Diabetes (T1D), with a limited operating history and significant going concern risks due to insufficient capital to fund operations beyond the near term.
- Aditxt is developing ADI-100, a preclinical immunomodulatory therapy for Type 1 Diabetes (T1D), which has shown no drug toxicity, no antibody formation, and no impairment of immune response in nonclinical studies [sec_mda · as of 2026-05-20].
- The company has an accumulated deficit of $181,061,686 as of June 30, 2025 [sec_mda · as of 2025-08-14].
- As of March 31, 2026, Aditxt reported cash and equivalents of $0.3M, total revenue of $0.0M, and a net loss of -$15.9M [sec].
- Aditxt is over 90 days past due on a significant number of vendor obligations and believes its remaining funds will not be sufficient to fund operations for the next 12 months, creating substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-20].
- The company plans to seek additional capital through equity or debt offerings, collaborative agreements, or government grants, which may result in dilution or restrictive covenants [sec_mda · as of 2026-05-20].
What works
- Aditxt's lead candidate, ADI-100, has demonstrated a favorable preclinical safety profile, including absence of drug toxicity, no antibody formation, and no impairment of immune response to infection or cancer [sec_mda · as of 2026-05-20].
- Clinical-grade GMP drug substance for ADI-100 has been successfully manufactured and is being prepared for final formulation and stability studies [sec_mda · as of 2026-05-20].
What to weigh
- Aditxt has incurred substantial operating losses since inception and expects to continue doing so, with an accumulated deficit of $181,061,686 as of June 30, 2025 [sec_mda · as of 2025-08-14].
- The company is over 90 days past due on a significant number of vendor obligations and has substantial doubt about its ability to continue as a going concern beyond one year [sec_mda · as of 2026-05-20].
- Aditxt's proposed acquisition of Cellvera is unlikely to be completed due to the target company's liquidation proceedings [sec_mda · as of 2025-08-14].
From the filings
Quoted directly from source documents.
ADI-100 preclinical safety profile
“Preclinical safety and toxicology studies have shown absence of drug toxicity, no antibody formation to the drug product, and a lack of persistence in all organs evaluated except the skin (at the injection site).”
SEC MD&A · May 20, 2026
Going concern uncertainty
“We believe our remaining funds on hand will not be sufficient to fund our operations for the next 12 months and such creates substantial doubt about our ability to continue as a going concern beyond one year.”
SEC MD&A · May 20, 2026
Accumulated deficit
“As of June 30, 2025, we had an accumulated deficit of $181,061,686.”
SEC MD&A · August 14, 2025
Vendor payment delinquency
“We are currently over 90 days past due on a significant number of vendor obligations.”
SEC MD&A · May 20, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Cash of $0.3M as of 2026-03-31 is insufficient to fund operations for 12 months, with substantial doubt about viability [sec_mda · as of 2026-05-20].
- Vendor delinquency — Company is over 90 days past due on significant vendor obligations, risking supply chain disruptions [sec_mda · as of 2026-05-20].
- Dilution risk — Future capital raises through equity or convertible debt may cause significant dilution to existing stockholders [sec_mda · as of 2026-05-20].
- Acquisition failure — Proposed acquisition of Cellvera is unlikely to complete due to target's liquidation proceedings [sec_mda · as of 2025-08-14].
What to watch
- Ability to raise additional capital through equity, debt, or partnerships to fund operations and clinical trials [sec_mda · as of 2026-05-20].
- Progress of ADI-100 GMP manufacturing and initiation of stability studies for clinical supply [sec_mda · as of 2026-05-20].
- Resolution of vendor payment delinquency and its impact on operational continuity [sec_mda · as of 2026-05-20].
- Any updates on the Cellvera acquisition or alternative antiviral portfolio strategies [sec_mda · as of 2025-08-14].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Aditxt, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aditxt, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
0.3 months
OCF -$5M · Net income -$16M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
12 buys · 12 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$19K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 11,721 | $11K |
| morgan stanley | 8,002 | $8K |
| danske bank a/s | 3 | $3 |
| group one trading llc | 2 | $2 |
| western wealth management, llc | 1 | $1 |
| ubs group ag | 1 | $1 |
| osaic holdings, inc. | 2 | $0 |
| darwin wealth management, llc | 1 | $0 |
Short Interest
as of May 20, 2026- % of float
- 27.0%
- Days to cover
- 0.1
- Shares short
- 9,058
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aditxt, Inc.?
Aditxt, Inc. is a clinical-stage biotechnology company focused on developing immunomodulatory therapies, including a preclinical candidate for Type 1 Diabetes (T1D), with a limited operating history and significant going concern risks due to insufficient capital to fund operations beyond the near term.
Who is the CEO of Aditxt, Inc.?
Mr. Jeffrey M. Busch J.D. is the chief executive officer of Aditxt, Inc. (ADTX).
Where is Aditxt, Inc. headquartered?
Aditxt, Inc. (ADTX) is headquartered in Mountain View, CA, United States.
What therapeutic areas does Aditxt, Inc. focus on?
Aditxt, Inc. develops therapies across Oncology, Immunology, Metabolic, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.